FK506 IN PEDIATRIC KIDNEY-TRANSPLANTATION - PRIMARY AND RESCUE EXPERIENCE by SHAPIRO, R et al.
----------
FKS06 IN PEDIATRIC KIDNEY TRANSPLANTATION· 
PRIMARY AND RESCUE EXPERIENCE 
Ron Shapiro MD, Velma P. Scantlebury MD, Mark L. Jordan MD, Carlos Vivas MD, 
Andreas G. Tzakis MD, Demetrius Ellis MD, Nisan Gilboa MD, Laszlo Hopp MD, 
Jerry McCauley, MD, William Irish MS, Sandi Mitchell MSIS, Thomas R. Hakala, MD, 
Richard L. Simmons MD, Thomas E. Starzl MD, Ph.D. 
Pittsburgh Transplantation Institute, Department of Surgery 
University of Pittsburgh Health Science Center of Pittsburgh 
Pittsburgh, PA 15213 
Address Reprint Requests to: Ron Shapiro, M.D. 
3601 Fifth Avenue 
4th Floor Falk Clinic 
Pittsburgh, PA 15213 
Phone: 412-648-3200 
FAX: 412-648-3184 
ABSTRACT 
Between December 14, 1989, and December 17, 1993,43 patients undergoing kidney 
transplantation alone at the Children's Hospital of Pittsburgh received FK506 as the primary 
immunosuppressive agent. The mean recipient age was 10.2 ± 4.8 years (range 0.7 - 17.4), 
with 7 (16%) children under 5 years of age and 2 (5%) under 2 years of age. Fifteen (35%) 
children underwent retransplantation, and 5 (12%) had a panel reactive antibody level 
greater than 40%. Twenty-two (51%) cases were with cadaveric donors, and 21 (49%) were 
with living donors. The mean follow-up is 25 ± 14 months. There were no deaths. One 
and three year actuarial graft survival was 98% and 85%. The mean serum creatinine and 
BUN were 1.2 ± 0.6 mg/dl and 26 ± 11 mg/dl; the calculated creatinine clearance was 75 
± 23 ml/min/1.73 m2• Twenty-four (62%) patients have been successfully withdrawn from 
steroids, and 24 (62%) require no anti-hypertensive medication. Improved growth was seen, 
particularly in pre-adolescent children off steroids. 
Between July 28, 1990, and December 2, 1993,24 children were referred for rescue 
therapy with FK506, 14.6 ± 16.4 months (range 1.1 - 53.2) after transplantation. Nineteen 
(79%) were referred because of resistant rejection; 4 (17%) were referred because of 
proteinuria; 1 (4%) was switched because of steroid-related obesity. There were no deaths. 
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One and two year graft survival was 75% and 68%. Seventeen (71%) patients were 
successfully rescued, including 1 of 2 patients who arrived on dialysis. Four (24%) of the 
successfully rescued patients were weaned off steroids. 
While not without side effects, which include nephrotoxicity, neurotoxicity, 
diabetogenicity, and viral complications, FK506 appears to be an effective 
immunosuppressive agent for both primary and rescue therapy after kidney transplantation. 
Its steroid-sparing qualities may be of particular importance in the pediatric population. 
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INTRODUCTION 
FK506 (Tacrolimus - trade name Prograf®) is a new immunosuppressive agent 
isolated from the soil organism Streptomyces Tsukubaensis. It has well described in vitro 
and experimental in vivo immunosuppressive properties I, and has been used in clinical 
heart2, lun~, liver\ lddney>-9, intestinallO, and isletll transplantation. The initial experiences 
in pediatric kidney transplantation have been previously described.12-16 Patient and graft 
survival have been comparable to that seen under cyclosporine immunosuppression, but 
lower steroid and antihypertensive requirements have been observed with FIG06.14-16 In 
addition, improved growth has been demonstrated in certain subgroups of children on 
FK506.14 Of some concern has been the suggestion of a higher incidence of viral 
complications associated with FK506, although they have all resolved without graft loss or 
patient death.15,16 
FK506 has also been used in an attempt to salvage patients transplanted under 
cyclosporine immunosuppressionp,18 The most common indication has been resistant acute 
rejection, and a success rate of 70 - 75% in unselected adults and children has been 
achieved. Most of these patients have received one or more courses of antilymphocyte 
therapy, and a smaller number of patients were on or had returned to dialysis prior to the 
initiation of rescue therapy. 
In this paper, we summarize our experience to date with both primary and rescue 
therapy with FK506 in pediatric kidney transplantation. 
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PATIENTS AND METHODS 
Primary Group 
Forty-three consecutive patients undergoing 43 kidney transplantations only at the 
Children's Hospital of Pittsburgh between 12/14/89 and 12/17/93 and receiving FK506 as 
the primary immunosuppressive agent were available for analysis (Table 1). Patients 
undergoing concomitant or previous liver transplantation were excluded. The mean 
recipient age was 10.2 ± 4.8 (range 0.7 - 17.4) years; 7 (16%) were under 5 years, and 2 
(5%) were under 2 years of age. There were 28 (65%) boys and 15 (35%) girls. Twenty-
eight (65%) patients were receiving their first transplant, and 15 (35%) were undergoing 
retransplantation. Just over half of the retransplant cases had been previously transplanted 
at other centers. Five (12%) patients (all retransplants) had a panel reactive antibody level 
greater than 40%. The causes of end stage renal disease are listed in Table 2. 
Twenty-two (51%) patients received kidneys from cadaver donors with a mean cold 
ischemia time of 31.2 ± 8.6 (range 12.1 - 45.1) hours, and an average HLA antigen match 
of 2.1 ± 1.3 and mismatch of 3.6 ± 1.2. There was one (5%) 6 antigen match. Five (23%) 
donors were 1 - 5 years of age. In two cases, the donors were 1 and 1.2 years old, and both 
kidneys were transplanted en bloc; in the other 3 cases, single kidneys from donors 3, 4, and 
5 years of age were transplanted. The recipients of these pediatric kidneys were older 
children, 10.3 - 16.7 years of age. Twenty-one (49%) patients received kidneys from living 
donors; there were 19 parents, 1 grandmother, and 1 adoptive father. The mean donor age 
was 29.6 ± 15.1 (range 1 - 50) years for all patients. 
Immunosuppression was with FK506 and steroids, as has been described 
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previously;15.16 azathioprine was also used initially in 18 (42%) patients. Induction therapy 
with antilymphocyte preparations was not used, although it was administered for steroid-
resistant rejection episodes. Over 90% of rejection episodes were biopsy-proven. 
Rescue Group 
Between July 28, 1990, and December 2, 1993, twenty-four patients were admitted 
to the Children's Hospital of Pittsburgh for FK506 rescue, 14.6 ± 16.4 (range 1.1 - 53.2) 
r 
months after transplantation (Table 3). The mean age at the time of transplantation was 
10.7 ± 4.5 (range 0.6 - 16.8) years. Twenty (83%) patients had undergone their first 
transplant, and 4 (17%) had undergone retransplantation. Nineteen (79%) had received 
kidneys from cadaveric donors, and 5 (21%) had received kidneys from living related 
donors. Nineteen (79%) patients had experienced acute rejection resistant to both steroids 
and antilymphocyte preparations. Four (17%) were switched because of proteinuria after 
transplantation19, and 1 (4%) was switched in an attempt to reduce steroid-related obesity. 
Three (12%) patients had been transplanted at the Children's Hospital of Pittsburgh; the 
remaining 21 (88%) patients had been transplanted at 11 other centers in United States. 
In general, switch-over was from oral cyclosporine to oral FK506 0.15 mg/kg twice 
daily; the patient's azathioprine and prednisone dosage were not initially changed. The 
FK506 dosage was then adjusted according to the levels; where possible, azathioprine and 
prednisone dosages were reduced after renal function had stabilized. 
Statistical Analysis 
For the primary FK506-treated group, patient survival was calculated from the date 
of kidney transplantation until death, and graft survival from the date of kidney 
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transplantation until graft failure, retransplantation, or patient death. Survival curves were 
generated using the Kaplan-Meier (product limit) method and were compared using the 
logrank (Mantel-Cox) test. All tests were two-tailed. A p-value less than 0.05 was 
considered statistically significant. 
For the rescue group, patient survival was calculated from the date 'of initiation of 
FK506 until death, and graft survival from the date of initiation of FK506 until graft failure, 
retransplantaion, or patient death. Cox's proportional hazards model was used to calculate 
the actuarial graft survival, taking into account the median time, after kidney 
transplantation, when FK506 was started. 
The standard two-sample t-test was used to test differences between means, while 
differences in proportion were tested using Pearson's Chi-square test of association. The 
Wilcoxon Rank Sum test, a non-parametric equivalent to the standard two-sample t-test was 
used for highly skewed data. 
RESULTS 
Primary Group 
The mean follow-up is 25 ± 14 months. All patients are alive. The overall one- and 
three-year actuarial graft survival is 98% and 85% (Figure 1). Four kidneys have been lost, 
at 0.3, 13.5,20.7, and 29.0 months, to recurrent hemolytic uremic syndrome, rejection, non-
compliance, and recurrent membranoproliferative glomerulonephritis, Type II. The one-
and three-year actuarial graft survival for specific subgroups is shown in Table 4. Of note, 
all the kidneys from the donors 5 years of age or younger are functioning well 9 - 52 months 
after transplantation. 
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The mean serum creatinine and BUN were 1.2 ± 0.6 mg/ dl and 26 ± 11 mg/ dl. The 
calculated creatinine clearance was 75 ± 23 ml/minute/1.73m2•20 
The incidence of early non-function was 7.0%; 2 (5%) patients required dialysis after 
transplantation. 
Acute rejection was seen 25 (58%) patients; antilymphocyte therapy was required in 
3 (7%) patients. Eighty-eight percent of the rejections were steroid-responsive. The 
incidence of rejection was not statistically different between living donor (67% - 14/21) and 
cadaver donor (50% - 11/22) (p=0.27) cases. The incidence in rejection in children less 
than 5 years of age, between 5 and 10 years, and greater than 10 years, was 57%, 53%, and 
62% (p=ns). In patients receiving triple drug therapy with azathioprine, the incidence of 
rejection was 61 %; in those patients starting on double drug therapy, the incidence was 56%. 
Cytomegalovirus was seen in 6 (14%) patients and was treated with intravenous 
gancyclovir. Post-transplant lymphoproliferative disorder (PTLD) was seen in 5 (12%) 
patients and was treated with reduction or temporary cessation of immunosuppression and 
intravenous gancyc10vir or acyclovir. In addition, 1 patient developed Epstein-Barr virus 
gastritis without PTLD was treated with gancyclovir and reduction of immunosuppression, 
and 1 patient developed a transient liver lesion that was not proven to be PTLD but 
disappeared with reduction of immunosuppression. No grafts were lost in the process of 
treating these complications, and all patients recovered. 
Transient new onset diabetes mellitus was seen in 3 (7%) patients and disappeared 
with reduction in the FK506 and steroid dosages. 
The mean dosage of FIG06 was 0.19 ± 0.15 mg/kg/d. The mean level was 0.56 ± 
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0.33 ng/ml. 
24 (62%) patients have had maintenance steroids discontinued. 3 (8%) additional 
patients have had steroids discontinued and then resumed because of rejection. The overall 
mean prednisone dose is 3.0 ± 5.0 mg/d (0.1 ± 0.1 mg/kg/d). The mean prednisone dose 
in those patients still on steroids is 7.1 ± 4.8 mg/d (0.2 ± 0.1 mg/kg/d). 
The growth patterns in patients on and off steroids are shown in Table 5. In general, 
there was a trend toward improving Z scores over time in all patients; not surprisingly, this 
was more pronounced in those children who were off steroids. When the analysis was 
further subdivided into pre-adolescents and adolescents, the most striking growth 
improvement was in the pre-adolescent children off steroids. This is in accord with our 
previous observations,14 but the magnitude of improvement in growth is more pronounced. 
At most recent follow-up, the Z score for the pre-adolescents off steroids was + 0.92. 
24 (62%) patients are off antihypertensive medications. The mean serum cholesterol 
is 178 ± 53 mg/dl. 
Rescue Group 
The mean follow-up, after initiation of FIG06 is 20.3 ± 11.7 months. None of the 
24 patients died after beginning rescue therapy. The one and two-year actuarial graft 
survival is 75% and 68% (Figure 2). 7/24 (29%) patients have unequivocally failed FIG06 
rescue therapy and have returned to dialysis, representing a success rate of 71%. For 
patients undergoing rescue for rejection, the success rate was 74% (14/19); for those 
patients with proteinuria, it was 50% (2/4); and the 1 patient with steroid-associated obesity 
was successfully switched and withdrawn from steroids. The success rate for cadaver and 
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living donor kidney recipients was 74% (14/19) and 60% (3/5), respectively. 13/20 (65%) 
of patients undergoing their first transplant was successfully rescued and 4/4 (100%) of the 
retransplant patients were switched successfully. Two patients were on dialysis at the time 
of initiation of rescue therapy, and 1 was successfully rescued. 
The mean serum creatinine prior to and after rescue was 2.0 ± 1.2 mg/dl and 1.9 ± 
1.0 mg/ dl; the corresponding BUN was 42 ± 38 and 32 ± 11. Calculated creatinine 
clearance was 47.1 ± 27.9 ml/min/1.73m2 and 51.5 ± 19.3 ml/min/1.73m2. The dosage of 
FK506 was 0.25 ± 0.14 mg/kg/d; the level was 0.67 ± 0.45 ng/ml. The mean prednisone 
dose before and after rescue was 16.8 ± 10 and 5.4 ± 5.0 mg/d (p=0.01). 4 (24%) patients 
have been weaned off prednisone after successful rescue. 
There was 1 case of cytomegalovirus in the rescue group that was diagnosed at the 
time of transfer for switchover to FK506. Gancylovir was administered, and FK506 was 
started; the patient recovered uneventfully. There was one case of PTLD occurring within 
one month after switchover; immunosuppression was discontinued, and the patient was 
treated with gancyclovir. The PTLD resolved, but the allograft was lost. 
DISCUSSION 
The evaluation of new immunosuppressive agents is more difficult than it was 10 -
15 years ago, because of the better results achieved with cyclosporine-based regimens. In 
fact, our recent retrospective comparison of cyclosporine and FK506 in pediatric kidney 
transplantation demonstrated comparable patient and graft survival; the big difference was 
in the ability to discontinue steroids in over half of the FK506-treated patients, and in the 
associated improvement in growth.14-16 The current update confirms the ability to wean a 
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substantial number of children off steroids under FK506 immunosuppression. The resultant 
improvement in growth makes FK506 a particularly attractive agent in pediatric 
transplantation. 
Unfortunately, an important complication seen initially with FK506 in pediatric renal 
transplant recipients was an increase in viral complications, including PTLD. Fortunately, 
these complications all resolved without patient or graft loss. With increasing experience, 
the incidence of significant viral complications has decreased, and there have been no new 
cases of PTLD in the patients transplanted in the past year. 
There is little question that FK506 is a nephrotoxic agent21-23 ; this toxicity seems 
comparable to that seen with cyclosporine.24,25 It is noteworthy that, in a protocol that did 
not employ induction therapy and that used intravenous FK506, the incidence of early 
nonfunction requiring dialysis was only 5%. 
Rejection has remained an important problem in our pediatric renal transplant 
population receiving FK506, with an incidence of 58%. While 88% of these rejections are 
steroid-responsive, and only 1 kidney has been lost to rejection, the overall incidence is still 
high. We have used a third agent, azathioprine, as an attempt to reduce the incidence of 
acute rejection, but have not seen any benefit. Parenthetically, in a prospective randomized 
trial in adult renal transplant recipients, a comparison of FIG06 and prednisone with FIG06, 
azathioprine, prednisone showed somewhat less acute rejection in the triple drug group but 
no improvement in graft survival.9 Sequential four drug therapy is being used in an ongoing 
multicenter randomized trial comparing FK506 and cyclosporine, and it will be useful to see 
whether the use of induction antilymphocyte therapy with FK506 will reduce the incidence 
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of acute rejection. In addition, there are a number of new immunosuppressive agents that 
are being evaluated, such as RS6144326, Brequinar7, Rapamycin28, Leflunomide29, and 15-
Deoxyspergualin30; perhaps one or more of these agents, in combination with FK506, will 
be effective in helping to reduce the incidence of acute rejection. 
The use of FK506 to rescue rejecting renal allografts or to turn off proteinuria after 
transplantation remains a bit mysterious. The success rate of 71 % is the same as that 
reported in the larger series reported by Jordan et a1.17,18 The success rate might 
conceivably have been higher but for a fairly broad willingness to accept patients for rescue 
therapy. Until the spring of 1994, FK506 remained investigational, and the ability to use 
it as a rescue agent for renal transplantation patients was limited, with few exceptions, to 
a single center. There has been a tendency, therefore, to accept virtually all patients 
referred, because of the perception that conversion to FK506 was the last hope. In the 
process, patients with fairly significant scarring have been switched over, with less than 
satisfactory results. As has been detailed in previous papers, fibrosis or chronic rejection 
are relative contraindications for switch over to FK506 in renal transplant patients. 
That having been acknowledged, the ability to salvage the majority of patients and 
restore good renal function to a child who arrived on dialysis remains difficult to understand. 
Our understanding of the mechanism of action of FK506, in blocking the initiation of IL-2 
mRNA transcription, does not per se explain its ability to reverse rejection in renal and 
other solid organ allografts. There may well be some anti-rejection property of the agent 
is, as yet, not well understood. In any event, the clinical phenomenon is real and has helped 
salvage a number of patients. Where it has failed, the reasons have been unremitting 
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rejection, extensive prior scarring or other chronic changes, or proteinuria secondary to 
irreversible morphologic changes. A few of the early successes have gone on to have some 
deterioration in renal function, related, in some cases, to noncompliance, or in other cases, 
to the presence (or perhaps progression) of chronic processes. Fortunately, no deaths have 
been ascribed to FlG06 rescue in the pediatric renal transplant population. 
The next ten years will see major changes in the immunosuppressive armamentarium, 
as more agents pass through the investigative pipeline and are approved for clinical use. 
The number of possible drug combinations will be large, and sorting out the most effective 
ones will be a complex process. It is clear, based on its immunosuppressive efficacy as a 
primary and rescue agent, and its steroid-sparing capability, that FK506 will be one of the 
most important of these new agents. The challenge will be to develop the ways to minimize 
its nephrotoxicity and not sacrifice its immunosuppressive advantages. 
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Figure 1: 
Figure 2: 
FIGURE LEGENDS 
Pediatric Kidney Transplantation Under FK506. Primary Group - Patient and 
Graft Survival. 
Pediatric Kidney Transplantation Under FK506. Rescue Group - Patient and 
Graft Survival. 
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N 
Age 
Under 5 Years 
Under 2 Years 
M/F 
First Transplant 
Retransplant 
PRA < 40% 
PRA> 40% 
Cadaver Donor 
Living Donor 
TABLE 1 
PRIMARY GROUP - RECIPIENT DEMOGRAPHICS 
43 
10.2 ± 4.8 years 
(range 0.7 - 17.4) 
7 (16%) 
2 (5%) 
28 (65%)/15 (35%) 
28 (65%) 
15 (35%) 
38 (88%) 
5 (12%) 
22 (51%) 
21 (49%) 
TABLE 2 
PRIMARY GROUP. CAUSES OF END STAGE RENAL DISEASE 
Glomerulonephritis 6 (14%) 
Obstructive Uropathy 5 (12%) 
Congenital Dysplasia 5 (12%) 
FSGS 5 (12%) 
HUS 4 (9%) 
Prune Belly 3 (7%) 
Congenital Hypoplasia 2 (5%) 
Polycystic Kidney 2 (5%) 
Cystinosis 1 (2%) 
Nepbronophthisis 1 (2%) 
IgA Nephropathy 1 (2%) 
Alport's 1 (2%) 
Reflux 1 (2%) 
Other 5 (12%) 
Unknown 1 (2%) 
43 
TABLE 3 
RESCUE GROUP - RECIPIENT DEMOGRAPHICS 
N 
Age (At time of transplantation) 
Time to Rescue (after transplantation) 
M/F 
First Transplant 
Retransplant 
Cadaver Donor 
Living Donor 
Indication 
Rejection 
Proteinuria 
Obesity 
Transplant Center 
Pittsburgh 
Elsewhere 
24 
10.7 ± 4.5 years 
(range 0.6 - 16.8) 
14.6 ± 16.4 months 
(range 1.1 - 53.2) 
10 (42%)/14 (58%) 
20 (83%) 
4 (17%) 
19 (79%) 
5 (21%) 
19 (79%) 
4 (17%) 
1 (4%) 
3 (12%) 
21 (88%) 
TABLE 4 
PRIMARY GROUP - AcruARIAL SURVIVAL 
1 Year 3 Year 
Patient Survival 
Overall 100% 100% 
Graft Survival 
Overall 98% 85% 
Cadaveric 95% 88% 
Living Donor 100% 84% 
Recipients < 2 years 100% 100% 
>2, < 5 years 80% 80% 
> 5 years 100% 86% 
Rejection 100% 80% 
No Rejection 94% 94% 
-----_._-_._-
At Transplant 
3 Months 
6 Months 
1 Year 
Most Recent 
Time 
At Transplant 
3 Months 
6 Months 
1 Year 
Most Recent 
TABLE 5 
PRIMARY GROup· GROWfH PATTERNS 
Z-score (± sd) 
OVERALL ON STEROIDS OFF STEROIDS 
·2040 (± 1.58) -2.22 (± 1.80) -2.54 (± 1.27) 
-2.04 (± 1.37) -2.17 (± 1.10) -1.94 (± 1.55) 
-1.46 (± 1.57) -1.76(± 1.32) -1.30 (± 1.70) 
-0.65 (± 1.89) -0.94(± 1.48) -0.55 (± 2.03) 
-0.31 (± 2.02) -0.92 (± 1.71) + 0.11 (± 2.41) 
ON STEROIDS OFF STEROIDS 
:S 12 Years > 12 Years :S 12 Years > Years 
-1.9 (± 1.2) -3.0 (± 1.1) -2.7 (± 1.3) -2.3 (± 2.6) 
-1.7 (± 0.9) -2.9 (± 1.0) -1.5 (± 0.7) -2.6 (± 2.3) 
-1.2 (± 1.2) -2.7 (± 1.1) -0.8 (± 0.8) -2.1 (± 2.5) 
-004 (± 1.1) -2.l (± 1.1) -0.02 (± 1.7) -1.6 (± 2.4) 
-0.42 (± 1.7) -2.0 (± 1.1) +0.92 (± 1.64) -1.4 (± 2.3) 
